Last reviewed · How we verify
NCT06732648
The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial
Phase 2/Phase 3 trial testing HRS8179 injection in Severe Cerebral Edema Following Large Hemispheric Infarction in 725 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Beijing Suncadia Pharmaceuticals Co., Ltd |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 725 |
| Start date | 7 February 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- HRS8179 injection
- HRS8179 blank preparation. — full drug profile →
Conditions studied
- Severe Cerebral Edema Following Large Hemispheric Infarction — all drugs for Severe Cerebral Edema Following Large Hemispheric Infarction →
Sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd — full company profile →
Who can join
Adults 18 to 80, any sex, with Severe Cerebral Edema Following Large Hemispheric Infarction. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Mortality rate at Day 90
Time frame: at Day 90
Sponsor's own description
The study is being conducted to evaluate the efficacy, and safety of HRS8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06732648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Suncadia Pharmaceuticals Co., Ltd trials
Trials by the same sponsor.
- NCT06825416 — A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplas · Phase 3 · completed
- NCT06723652 — A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety · Phase 3 · completed
- NCT06471218 — Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia · Phase 2 · completed
- NCT06280768 — Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With · Phase 1 · unknown
- NCT06220123 — A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06732648 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Suncadia Pharmaceuticals Co., Ltd
- Last refreshed: 18 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06732648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing